Freedom Broker Issues Positive Forecast for Pfizer (NYSE:PFE) Stock Price

Pfizer (NYSE:PFE) had its target price hoisted by Freedom Broker from $33.00 to $34.00 in a report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on PFE. Scotiabank boosted their price objective on Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a research report on Wednesday. HSBC lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Royal Bank Of Canada boosted their price target on shares of Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a report on Wednesday. FBN Securities set a $34.00 price objective on shares of Pfizer in a research report on Friday. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Six investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $30.39.

Pfizer Stock Performance

Pfizer stock traded down $0.50 during mid-day trading on Friday, reaching $29.38. 48,291,518 shares of the company traded hands, compared to its average volume of 30,697,644. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer has a fifty-two week low of $23.62 and a fifty-two week high of $31.44. The company has a market capitalization of $167.46 billion, a price-to-earnings ratio of 41.97, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. The firm’s fifty day moving average is $28.74 and its two-hundred day moving average is $26.90.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. The business had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.87 earnings per share. On average, equities research analysts expect that Pfizer will post 3.03 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is presently 245.71%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC lifted its stake in shares of Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 509 shares in the last quarter. Keb Asset Management LLC purchased a new stake in Pfizer during the 2nd quarter valued at about $26,000. Field & Main Bank acquired a new stake in Pfizer in the 2nd quarter valued at about $27,000. Bullseye Investment Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at about $28,000. Finally, Timbuktu Capital Management LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

About Pfizer